Harnessing the body’s response to leptospirosis for diagnosis and prognosis
Official title: Harnessing the Host Response to Leptosporisis for Diagnosis and Prognosis
Funded at University of California Los Angeles · NIH-11533862 · Data updated 2026-11-12
A multi-site team is working to develop how the body naturally responds to leptospirosis to improve how we diagnose the infection and predict its course.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | May 1, 2025 |
| Project end | April 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $62,500 |
| NIH project number | 3P01AI168148-04S2 |
| Project ID | NIH-11533862 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals suspected of or diagnosed with leptospirosis who can provide clinical data and samples.
✕Less likely to help
People without leptospirosis or those not contributing to the biomarker analyses may not benefit directly.
What this research studies
This project aims to translate what the body’s immune and physiological signals do when someone has leptospirosis into clearer tests and clues about how severe the illness may become. Researchers plan to combine biological data from patients with analytical methods to create better diagnostic and prognostic tools. The work will involve clinical samples and data from people with leptospirosis to identify useful markers. If successful, this could help doctors identify infections earlier and tailor care to each patient.
Why it matters
Potential benefit: If successful, patients with leptospirosis could receive faster, more accurate diagnoses and smarter predictions about disease progression.
How similar studies have gone: Previous work has shown promise in identifying host-response markers for infectious diseases, but this specific approach for leptospirosis is being tested.
Where this research is happening
-
University of California Los Angeles
Los Angeles, United States Active
Researchers
- Principal investigator: Haake, David a — University of California Los Angeles
- Study coordinator: Haake, David a
Related research
Other NIH-funded projects on the same topics.
-
Colorectal cancer prognosis through a broad, collaborative study
A large, multi-center study follows people newly diagnosed with colorectal cancer to find biomarkers and patterns that predict outcomes and guide future care.
-
AI-powered digital pathology to tailor cancer treatment decisions
A team at Emory is building an AI-powered platform that analyzes cancer slides to help doctors choose the right therapies and avoid unnecessary chemotherapy or radiation for patients.
-
Harnessing the body's response to leptospirosis to aid diagnosis and prognosis
This grant aims to develop new ways to detect leptospirosis earlier and predict how severe it might become by studying the body's own response.
-
Harnessing the body’s response to Leptospirosis to improve diagnosis and prognosis
A research program at UCLA aims to use how the body responds to leptospirosis to make better diagnoses and predict outcomes for patients.
-
Harnessing the body's response to a dangerous infection to help diagnose and predict outcomes
A large, multi-project effort aims to use how the body reacts to leptospirosis to improve diagnosis and prognosis for patients affected by this infection.
-
AI-powered tool to better predict and manage acute pulmonary embolism
A new AI system uses imaging and patient data to improve how doctors predict short-term risk and tailor treatment for people with acute pulmonary embolism.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.